JeffreyMStatlandMD

Neurology • Kansas City, KS

Neuromuscular Medicine

Assistant Professor, Neurology, University of Kansas Medical Center

Join to view full profile

Dr. Statland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Statland's full profile

Already have an account?

Office
3901 Rainbow Blvd
Stop 2012
Kansas City, KS 66160
Phone+1 913-588-6970

Fax+1 913-588-0609

Education & Training

University of Kansas School of MedicineResidency, Neurology, 2007 - 2010
University of Kansas School of MedicineResidency, Internal Medicine, 2006 - 2007
University of Kansas School of MedicineClass of 2005

Certifications & Licensure

KS State Medical License 2014 - 2025
MO State Medical License 2022 - 2025
CO State Medical License 2022 - 2023
WA State Medical License 2019 - 2023
NY State Medical License 2010 - 2014
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Rasch-analysis of Clinical Severity in FSHD Start of enrollment: 2016 Mar 01
Completed
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD Start of enrollment: 2018 Mar 05
Active, not recruiting
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Start of enrollment: 2018 Jun 11
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2021 Aug 16
Terminated
Phase 3
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Start of enrollment: 2019 Jan 01
Recruiting
Roles: Principal Investigator, Contact
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) Start of enrollment: 2023 May 31
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.
Salman Bhai, Todd Levine, Dan Moore, Robert Bowser, Andrew J Heim
Muscle & Nerve. 2025-01-01
Prospective observational study of FKRP-related limb-girdle muscular dystrophy R9: A GRASP consortium study.
Lindsay N Alfano, Meredith K James, Kristine Grosfjeld Petersen, Karen Rudolf, John Vissing
Annals of Clinical and Translational Neurology. 2024-12-15
2 citations
Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.
Michael Benatar, Eric A Macklin, Andrea Malaspina, Mary-Louise Rogers, Eran Hornstein
Ebiomedicine. 2024-10-01

Press Mentions

Avidity Biosciences Enters into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial UseAugust 16th, 2021
Muscular Dystrophy Association Virtual Conference to Feature Latest Advances in Neuromuscular Therapy and Clinical CareMarch 8th, 2021
FSHD Society Is Funding the Expansion of the FSHD Clinical Trial Research NetworkAugust 11th, 2020
Join now to see all